Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients

被引：25

作者：

Cattrini, Carlo ^{[1
,2
]}

Rubagotti, Alessandra ^{[1
,3
]}

Zinoli, Linda ^{[1
]}

Cerbone, Luigi ^{[1
,2
]}

Zanardi, Elisa ^{[1
,2
]}

Capaia, Matteo ^{[2
]}

Barboro, Paola ^{[1
]}

Boccardo, Francesco ^{[1
,2
]}

机构：

[1] IRCCS San Martino Polyclin Hosp, Acad Unit Med Oncol, I-16132 Genoa, Italy

[2] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DIMI, I-16132 Genoa, Italy

[3] Univ Genoa, Sch Med, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy

来源：

CANCERS | 2019年 / 11卷 / 09期

关键词：

AR-V7; AR-FL; castration-resistant prostate cancer; prognostic biomarkers; circulating tumor cells; ABIRATERONE; ENZALUTAMIDE;

D O I：

10.3390/cancers11091365

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Circulating tumor cells (CTC), androgen receptor full-length (AR-FL), and androgen receptor splice variant 7 (AR-V7) are prognostic in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). AR-V7 seems to predict resistance to androgen-receptor signaling inhibitors (ARSi). Methods: We assessed the association of CTC, AR-FL, and AR-V7 with prostate-specific antigen (PSA) response and overall survival (OS). We used a modified AdnaTest CTC-based AR-FL and AR-V7 mRNA assay. Chi-square test, Fisher Exact test, Kaplan-Meier method, log-rank test, Cox proportional hazards models were used as appropriate. Results: We enrolled 39 mCRPC pts, of those 24 started a first-line treatment for mCRPC (1L subgroup) and 15 had received at least two lines for mCRPC (>2L subgroup). CTC, AR-FL, and AR-V7 were enriched in >2L compared to 1L subgroup. Detection of these biomarkers was associated with a lower percentage of biochemical responses. Only 1/7 AR-V7+ pts had a PSA response and received cabazitaxel. Median OS was 4.7 months (95% CI 0.6-8.9) in AR-V7+ pts and not reached in AR-V7- pts. AR-V7 was the only variable with prognostic significance in the Cox model. Conclusion: AR-V7, CTC, and AR-FL are associated with advanced mCRPC and AR-V7+ predicts for shorter OS.

引用

页数：10

共 26 条

[1] Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Zhu, Yezi ;

Silberstein, John L. ;

Taylor, Maritza N. ;

Maughan, Benjamin L. ;

Denmeade, Samuel R. ;

Pienta, Kenneth J. ;

Paller, Channing J. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2149-+

[2] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

[3] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[4] Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Luo, Jun ;

Nanus, David M. ;

Giannakakou, Paraskevi ;

Szmulewitz, Russell Z. ;

Danila, Daniel C. ;

Healy, Patrick ;

Anand, Monika ;

Rothwell, Colin J. ;

Rasmussen, Julia ;

Thornburg, Blair ;

Berry, William R. ;

Wilder, Rhonda S. ;

Lu, Changxue ;

Chen, Yan ;

Silberstein, John L. ;

Kemeny, Gabor ;

Galletti, Giuseppe ;

Somarelli, Jason A. ;

Gupta, Santosh ;

Gregory, Simon G. ;

Scher, Howard I. ;

Dittamore, Ryan ;

Tagawa, Scott T. ;

Antonarakis, Emmanuel S. ;

George, Daniel J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1120-+

[5] Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study [J].

Conteduca, V. ;

Wetterskog, D. ;

Sharabiani, M. T. A. ;

Grande, E. ;

Fernandez-Perez, M. P. ;

Jayaram, A. ;

Salvi, S. ;

Castellano, D. ;

Romanel, A. ;

Lolli, C. ;

Casadio, V. ;

Gurioli, G. ;

Amadori, D. ;

Font, A. ;

Vazquez-Estevez, S. ;

Gonzalez del Alba, A. ;

Mellado, B. ;

Fernandez-Calvo, O. ;

Mendez-Vidal, M. J. ;

Climent, M. A. ;

Duran, I. ;

Gallardo, E. ;

Rodriguez, A. ;

Santander, C. ;

Saez, M. I. ;

Puente, J. ;

Tandefelt, D. Gasi ;

Wingate, A. ;

Dearnaley, D. ;

Demichelis, F. ;

De Giorgi, U. ;

Gonzalez-Billalabeitia, E. ;

Attard, G. .

ANNALS OF ONCOLOGY, 2017, 28 (07) :1508-1516

[6] Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer [J].

Conteduca, Vincenza ;

Jayaram, Anuradha ;

Romero-Laorden, Nuria ;

Wetterskog, Daniel ;

Salvi, Samanta ;

Gurioli, Giorgia ;

Scarpi, Emanuela ;

Castro, Elena ;

Marin-Aguilera, Mercedes ;

Lolli, Cristian ;

Schepisi, Giuseppe ;

Maugeri, Antonio ;

Wingate, Anna ;

Farolfi, Alberto ;

Casadio, Valentina ;

Medina, Ana ;

Puente, Javier ;

Mendez Vidal, Ma Jose ;

Morales-Barrera, Rafael ;

Villa-Guzman, Jose C. ;

Hernando, Susana ;

Rodriguez-Vida, Alejo ;

Gonzalez-del-Alba, Aranzazu ;

Mellado, Begona ;

Gonzalez-Billalabeitia, Enrique ;

Olmos, David ;

Attard, Gerhardt ;

De Giorgi, Ugo .

EUROPEAN UROLOGY, 2019, 75 (03) :368-373

[7] Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer [J].

Del Re, Marzia ;

Crucitta, Stefania ;

Sbrana, Andrea ;

Rofi, Eleonora ;

Paolieri, Federico ;

Gianfilippo, Giulia ;

Galli, Luca ;

Falcone, Alfredo ;

Morganti, Riccardo ;

Porta, Camillo ;

Efstathiou, Eleni ;

van Schaik, Ron ;

Jenster, Guido ;

Danesi, Romano .

BJU INTERNATIONAL, 2019, 124 (04) :693-700

[8]

Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO

[9]

2-4

[10] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

← 1 2 3 →